Elevated endogenous expression of the dominant negative basic helix-loop-helix protein ID1 correlates with significant centrosome abnormalities in human tumor cells

BMC Cell Biology

Volumn 11, Issue , 2010, Pages

  Manthey, Carolin ^a,b   Mern, Demissew S ^a,c   Gutmann, Anja ^a   Zielinski, Anne J ^a   Herz, Corinna ^a   Lassmann, Silke ^a   Hasskarl, Jens ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 3; MESSENGER RNA; ID1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CELL DIVISION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CENTROSOME; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOSIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; UTERINE CERVIX CANCER; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CENTROSOME; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MITOSIS; NEOPLASMS;

EID: 76749168105     PISSN: None     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-11-2     Document Type: Article

References (72)

1. Benezra R, Davis RL, Lassar A, Tapscott S, Thayer M, Lockshon D, Weintraub H. Id: a negative regulator of helix-loop-helix DNA binding proteins. Control of terminal myogenic differentiation. Ann N Y Acad Sci 1990, 599:1-11. 10.1111/j.1749-6632.1990.tb42359.x, 2171390.
2. Alani RM, Hasskarl J, Grace M, Hernandez MC, Israel MA, Munger K. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci USA 1999, 96(17):9637-9641. 10.1073/pnas.96.17.9637, 22262, 10449746.
3. Nickoloff BJ, Chaturvedi V, Bacon P, Qin JZ, Denning MF, Diaz MO. Id-1 delays senescence but does not immortalize keratinocytes. J Biol Chem 2000, 275(36):27501-27504.
4. Tang J, Gordon GM, Nickoloff BJ, Foreman KE. The helix-loop-helix protein id-1 delays onset of replicative senescence in human endothelial cells. Lab Invest 2002, 82(8):1073-1079.
5. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401(6754):670-677. 10.1038/44334, 10537105.
6. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7(11):1194-1201. 10.1038/nm1101-1194, 11689883.
7. Fraidenraich D, Stillwell E, Romero E, Wilkes D, Manova K, Basson CT, Benezra R. Rescue of cardiac defects in id knockout embryos by injection of embryonic stem cells. Science 2004, 306(5694):247-252. 10.1126/science.1102612, 1351017, 15472070.
8. Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 2003, 115(3):281-292. 10.1016/S0092-8674(03)00847-X, 14636556.
9. Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B, Birner P. Overexpression of id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res 2001, 61(15):5703-5706.
10. Polsky D, Young AZ, Busam KJ, Alani RM. The Transcriptional Repressor of p16/Ink4a, Id1, Is Up-Regulated in Early Melanomas. Cancer Res 2001, 61(16):6008-6011.
11. Maruyama H, Kleeff J, Wildi S, Friess H, Buchler MW, Israel MA, Korc M. Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol 1999, 155(3):815-822. 1866883, 10487839.
12. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Identification of Differentially Expressed Genes in Esophageal Squamous Cell Carcinoma (ESCC) by cDNA Expression Array: Overexpression of Fra-1, Neogenin, Id-1, and CDC25B Genes in ESCC. Clin Cancer Res 2001, 7(8):2213-2221.
13. Kebebew E. Id1 gene expression and regulation in human thyroid tissue. Thyroid 2005, 15(6):522-530. 10.1089/thy.2005.15.522, 16029118.
14. Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner P. Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer 2003, 104(6):677-682. 10.1002/ijc.11009, 12640673.
15. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of ID-1 in prostate cancer. J Urol 2002, 167(6):2598-2602. 10.1016/S0022-5347(05)65044-6, 11992094.
16. Schindl M, Schoppmann SF, Strobel T, Heinzl H, Leisser C, Horvat R, Birner P. Level of id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res 2003, 9(2):779-785.
17. Maw MK, Fujimoto J, Tamaya T. Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers. Br J Cancer 2008, 99(10):1557-1563. 10.1038/sj.bjc.6604722, 2584935, 19002177.
18. Hasskarl J, Duensing S, Manuel E, Munger K. The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers. Oncogene 2004, 23(10):1930-1938. 10.1038/sj.onc.1207310, 14755252.
19. Man C, Rosa J, Yip YL, Cheung AL, Kwong YL, Doxsey SJ, Tsao SW. Id1 overexpression induces tetraploidization and multiple abnormal mitotic phenotypes by modulating aurora A. Mol Biol Cell 2008, 19(6):2389-2401. 10.1091/mbc.E07-09-0875, 2397319, 18353975.
20. Wang X, Di K, Zhang X, Han HY, Wong YC, Leung SC, Ling MT. Id-1 promotes chromosomal instability through modification of APC/C activity during mitosis in response to microtubule disruption. Oncogene 2008, 27(32):4456-4466. 10.1038/onc.2008.87, 18372912.
21. Hasskarl J, Mern DS, Munger K. Interference of the dominant negative helix-loop-helix protein ID1 with the proteasomal subunit S5A causes centrosomal abnormalities. Oncogene 2008, 27(12):1657-1664. 10.1038/sj.onc.1210808, 17891176.
22. Nigg EA. Centrosome aberrations: cause or consequence of cancer progression?. Nat Rev Cancer 2002, 2(11):815-825. 10.1038/nrc924, 12415252.
23. Meraldi P, Nigg EA. The centrosome cycle. FEBS Lett 2002, 521(1-3):9-13. 10.1016/S0014-5793(02)02865-X, 12067716.
24. Hinchcliffe EH, Sluder G. Two for two: Cdk2 and its role in centrosome doubling. Oncogene 2002, 21(40):6154-6160. 10.1038/sj.onc.1205826, 12214244.
25. Doxsey S. Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol Cell 2002, 10(3):439-440. 10.1016/S1097-2765(02)00654-8, 12408813.
26. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol 1999, 1(2):88-93. 10.1038/10054, 10559879.
27. Doxsey S, McCollum D, Theurkauf W. Centrosomes in cellular regulation. Annu Rev Cell Dev Biol 2005, 21:411-434. 10.1146/annurev.cellbio.21.122303.120418, 16212501.
28. Mikule K, Delaval B, Kaldis P, Jurcyzk A, Hergert P, Doxsey S. Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest. Nat Cell Biol 2007, 9(2):160-170. 10.1038/ncb1529, 17330329.
29. Fukasawa K, Choi T, Kuriyama R, Rulong S, Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996, 271(5256):1744-1747. 10.1126/science.271.5256.1744, 8596939.
30. Mussman JG, Horn HF, Carroll PE, Okuda M, Tarapore P, Donehower LA, Fukasawa K. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene 2000, 19(13):1635-1646. 10.1038/sj.onc.1203460, 10763820.
31. De Luca A, Mangiacasale R, Severino A, Malquori L, Baldi A, Palena A, Mileo AM, Lavia P, Paggi MG. E1A deregulates the centrosome cycle in a Ran GTPase-dependent manner. Cancer Res 2003, 63(6):1430-1437.
32. Duensing S, Munger K. Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. J Virol 2003, 77(22):12331-12335. 10.1128/JVI.77.22.12331-12335.2003, 254291, 14581569.
33. Kramer A, Neben K, Ho AD. Centrosome replication, genomic instability and cancer. Leukemia 2002, 16(5):767-775. 10.1038/sj.leu.2402454, 11986936.
34. Acilan C, Saunders WS. A tale of too many centrosomes. Cell 2008, 134(4):572-575. 10.1016/j.cell.2008.08.007, 18724931.
35. Lingle WL, Lukasiewicz K, Salisbury JL. Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer. Adv Exp Med Biol 2005, 570:393-421. full_text, 18727509.
36. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000, 113(Pt 22):3897-3905.
37. Riechmann V, van Cruchten I, Sablitzky F. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res 1994, 22(5):749-755. 10.1093/nar/22.5.749, 307878, 8139914.
38. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009, 460(7252):278-282. 10.1038/nature08136, 2743290, 19506557.
39. Buitenhuis M, van Deutekom HW, Verhagen LP, Castor A, Jacobsen SE, Lammers JW, Koenderman L, Coffer PJ. Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2. Blood 2005, 105(11):4272-4281. 10.1182/blood-2004-12-4883, 15701714.
40. Ishiguro A, Spirin KS, Shiohara M, Tobler A, Gombart AF, Israel MA, Norton JD, Koeffler HP. Id2 expression increases with differentiation of human myeloid cells. Blood 1996, 87(12):5225-5231.
41. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 2000, 407(6804):592-598. 10.1038/35036504, 11034201.
42. Xiao X, Phogat SK, Sidorov IA, Yang J, Horikawa I, Prieto D, Adelesberger J, Lempicki R, Barrett JC, Dimitrov DS. Identification and characterization of rapidly dividing U937 clones with differential telomerase activity and gene expression profiles: role of c-Myc/Mad1 and Id/Ets proteins. Leukemia 2002, 16(9):1877-1880. 10.1038/sj.leu.2402607, 12200713.
43. Lofstedt T, Jogi A, Sigvardsson M, Gradin K, Poellinger L, Pahlman S, Axelson H. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 2004, 279(38):39223-39231. 10.1074/jbc.M402904200, 15252039.
44. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knuchel R, Dahl E. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 2008, 8(154). 2435120, 18513385.
45. Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Li R, So S, Yuen ST, Leung SY. Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene 2003, 22(44):6946-6953. 10.1038/sj.onc.1206799, 14534543.
46. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004, 10(22):7475-7483. 10.1158/1078-0432.CCR-04-0689, 15569977.
47. Hagiwara K, Nagai H, Li Y, Ohashi H, Hotta T, Saito H. Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma. J Clin Exp Hematop 2007, 47(1):15-18. 10.3960/jslrt.47.15, 17510533.
48. Uhm KO, Lee ES, Lee YM, Kim HS, Park YN, Park SH. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Oncol Res 2008, 17(4):151-157. 10.3727/096504008785114110, 18773859.
49. Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welcsh P, Welch PJ, Welte K, King MC, Barber JR, Wong-Staal F. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci USA 2001, 98(1):130-135. 10.1073/pnas.98.1.130, 14556, 11136250.
50. Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. Mol Cancer 2005, 4(1):16. 10.1186/1476-4598-4-16, 1131921, 15876350.
51. Bellido M, Aventin A, Lasa A, Estivill C, Carnicer MJ, Pons C, Matias-Guiu X, Bordes R, Baiget M, Sierra J, Nomdedeu JF. Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia. Haematologica 2003, 88(9):994-1001.
52. Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Loraine Karran E, Nagel I, Harder L, Claviez A, Gesk S, Moorman AV, Ross F, Mazzullo H, Strefford JC, Siebert R, Dyer MJ, Harrison CJ. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008, 111(1):387-391. 10.1182/blood-2007-07-092015, 17940204.
53. Bounpheng MA, Dimas JJ, Dodds SG, Christy BA. Degradation of Id proteins by the ubiquitin-proteasome pathway. Faseb J 1999, 13(15):2257-2264.
54. Ling MT, Kwok WK, Fung MK, Xianghong W, Wong YC. Proteasome mediated degradation of Id-1 is associated with TNFalpha-induced apoptosis in prostate cancer cells. Carcinogenesis 2006, 27(2):205-215. 10.1093/carcin/bgi217, 16123120.
55. Trausch-Azar JS, Lingbeck J, Ciechanover A, Schwartz AL. Ubiquitin-Proteasome-mediated degradation of Id1 is modulated by MyoD. J Biol Chem 2004, 279(31):32614-32619. 10.1074/jbc.M403794200, 15163661.
56. Deed RW, Hara E, Atherton GT, Peters G, Norton JD. Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation. Mol Cell Biol 1997, 17(12):6815-6821. 232537, 9372912.
57. Hara E, Hall M, Peters G. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. Embo J 1997, 16(2):332-342. 10.1093/emboj/16.2.332, 1169639, 9029153.
58. Lasorella A, Stegmuller J, Guardavaccaro D, Liu G, Carro MS, Rothschild G, de la Torre-Ubieta L, Pagano M, Bonni A, Iavarone A. Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. Nature 2006, 442(7101):471-474. 10.1038/nature04895, 16810178.
59. Jen Y, Manova K, Benezra R. Expression patterns of Id1, Id2, and Id3 are highly related but distinct from that of Id4 during mouse embryogenesis. Dev Dyn 1996, 207(3):235-252. 10.1002/(SICI)1097-0177(199611)207:3<235::AID-AJA1>3.0.CO;2-I, 8922523.
60. Doxsey SJ. Centrosomes as command centres for cellular control. Nat Cell Biol 2001, 3(5):E105-108. 10.1038/35074618, 11331889.
61. Mantel C, Braun SE, Reid S, Henegariu O, Liu L, Hangoc G, Broxmeyer HE. p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood 1999, 93(4):1390-1398.
62. Stavropoulou V, Xie J, Henriksson M, Tomkinson B, Imreh S, Masucci MG. Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II. Cancer Res 2005, 65(4):1361-1368. 10.1158/0008-5472.CAN-04-2085, 15735022.
63. Duensing S, Lee BH, Cin PD, Munger K. Excessive centrosome abnormalities without ongoing numerical chromosome instability in a Burkitt's lymphoma. Mol Cancer 2003, 2(1):30. 10.1186/1476-4598-2-30, 201009, 14498992.
64. Duensing S, Duensing A, Crum CP, Munger K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res 2001, 61(6):2356-2360.
65. zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999, 111(6):581-587. 10.1046/j.1525-1381.1999.99723.x, 10591087.
66. Gerlach U, Kayser G, Walch A, Hopt U, Schulte-Monting J, Werner M, Lassmann S. Centrosome-, chromosomal-passenger- and cell-cycle-associated mRNAs are differentially regulated in the development of sporadic colorectal cancer. J Pathol 2006, 208(4):462-472. 10.1002/path.1914, 16402339.
67. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, Werner M. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med 2007, 85(3):293-304. 10.1007/s00109-006-0126-5, 17143621.
68. Lassmann S, Danciu M, Muller M, Weis R, Makowiec F, Schulte-Monting J, Hopt UT, Werner M. Aurora A is differentially expressed and regulated in chromosomal and microsatellite instable sporadic colorectal cancers. Mod Pathol 2009, 22(10):1385-1397. 10.1038/modpathol.2009.111, 19648887.
69. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998, 20(2):189-193. 10.1038/2496, 9771714.
70. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 2007, 104(10):4106-4111. 10.1073/pnas.0608798104, 1820716, 17360485.
71. Gautschi O, Mack PC, Davies AM, Lara PN, Gandara DR. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer 2006, 8(2):93-98. 10.3816/CLC.2006.n.036, 17026809.
72. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.